This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years
This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years

This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years

With a PE ratio of 20x, the company trades at a discount compared to the industry PE of 28x. The company has ROCE of 22.3 per cent and ROE of 20.7 per cent.  

DSIJ Intelligence Article rating: 5.0
New Drug Launch: Transforming Cardiometabolic Care in India
New Drug Launch: Transforming Cardiometabolic Care in India

New Drug Launch: Transforming Cardiometabolic Care in India

Glenmark Pharmaceuticals Ltd, a prominent global pharmaceutical company, has expanded its cardiometabolic portfolio by launching Empagliflozin and its fixed-drug combinations in India.

DSIJ Intelligence Article rating: 5.0

The company continues to strengthen its presence in the cardiometabolic care segment, addressing the rising prevalence of diabetes and cardiovascular diseases in India.

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.
This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

DSIJ Intelligence Article rating: 3.7

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!
Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!

Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!

Notably, the RSI has entered a super bullish territory, indicating a significant shift in momentum.

DSIJ Intelligence Article rating: 4.7

The Nifty Pharmaceutical index has surged by an impressive 30 per cent on a year-to-date basis in 2023, significantly outperforming the Nifty 50 index. Against the backdrop of India experiencing a single-day spike of 628 new COVID-19 cases

Stocks to watch: These small-cap stocks will be in focus on Friday!
Stocks to watch: These small-cap stocks will be in focus on Friday!

Stocks to watch: These small-cap stocks will be in focus on Friday!

Among the BSE Smallcap gainers were Astec Lifesciences, Syncom Formulations, Suzlon Energy and NBCC

DSIJ Intelligence Article rating: 4.1

On Wednesday, the Sensex gained by 346 points to close at 57,960.09, while the Nifty 50 surged by 129 points to close at 17,080.70

Overnight Digest: Stocks to be watched on August 12
Overnight Digest: Stocks to be watched on August 12

Overnight Digest: Stocks to be watched on August 12

Keep an eye on these stocks for Friday's trading session.

DSIJ Intelligence Article rating: 4.3

Benchmark indices registered a positive close on Thursday with Sensex gaining 500 points while Nifty advancing 124 points. 

Stocks to watch: These small-cap stocks will be in focus tomorrow!
Stocks to watch: These small-cap stocks will be in focus tomorrow!

Stocks to watch: These small-cap stocks will be in focus tomorrow!

PC Jeweller, Ethos Ltd, Mirza International, Himadri Speciality Chemical, Shalimar Paints, Elecon Engineering, Sterling Tools, Brand Concepts, Kernex Microsystems, Sumitomo Chemical India, and Phoenix Mills made a fresh 52-week high today

DSIJ Intelligence Article rating: 3.9

BSE Smallcap index bucked the negative trend to outperform broader markets, climbing 1.07 per cent and ending the session at 25,916.41.

RSS
12

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR